Life at Lilly | GenomeWeb

Life at Lilly

It's tough times at Eli Lilly with patents ending, failed drugs, among other problems, reports the New York Times. But CEO John Lechleiter says that Lilly doesn't need to turn to mergers or acquisitions to jump-start the company; he says they can rely on in-house research and cost-cutting. "At a time when others say Lilly has to do a deal or Lilly has to go outside itself to solve its problems, we're resolutely focused on what we have to do inside the company," Lechleiter says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.